Spark Therapeutics (NASDAQ:ONCE) had its price target decreased by investment analysts at Chardan Capital from $100.00 to $60.00 in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 30.69% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on ONCE. UBS cut Spark Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $92.00 to $51.00 in a research note on Tuesday. BMO Capital Markets set a $73.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday. SunTrust Banks set a $101.00 price target on Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, October 16th. Leerink Swann cut Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 price target on the stock. in a research note on Tuesday. Finally, Evercore ISI began coverage on Spark Therapeutics in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $83.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $76.19.

Spark Therapeutics (NASDAQ ONCE) traded up $1.15 during midday trading on Tuesday, hitting $45.91. The stock had a trading volume of 1,895,700 shares, compared to its average volume of 481,123. Spark Therapeutics has a 12 month low of $41.06 and a 12 month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.07) EPS. analysts forecast that Spark Therapeutics will post -7.6 earnings per share for the current year.

In other Spark Therapeutics news, insider Daniel Faga sold 1,500 shares of the stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $85.00, for a total transaction of $127,500.00. Following the transaction, the insider now owns 1,500 shares in the company, valued at approximately $127,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.54, for a total value of $1,430,800.00. Following the transaction, the chief executive officer now owns 250,000 shares in the company, valued at approximately $17,885,000. The disclosure for this sale can be found here. Insiders have sold a total of 1,068,809 shares of company stock worth $89,809,385 in the last quarter. Company insiders own 7.30% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. increased its position in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Spark Therapeutics during the 2nd quarter worth $143,000. BNP Paribas Arbitrage SA grew its holdings in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 2,449 shares in the last quarter. Pacad Investment Ltd. grew its holdings in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Spark Therapeutics during the 3rd quarter worth $225,000. Hedge funds and other institutional investors own 94.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics (ONCE) PT Lowered to $60.00” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/spark-therapeutics-once-pt-lowered-to-60-00/1763776.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.